tradingkey.logo
tradingkey.logo
Buscar

Innate Pharma SA

IPHA
Añadir a la lista de seguimiento
2.180USD
-0.355-14.00%
Cierre 08-14 16:00ETCotizaciones retrasadas 15 min
202.21MCap. mercado
PérdidaP/E TTM

Más Datos de Innate Pharma SA Compañía

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Perfil de Innate Pharma SA

Símbolo de cotizaciónIPHA
Nombre de la empresaInnate Pharma SA
Fecha de salida a bolsaOct 31, 2006
Director ejecutivoDickinson (Jonathan Elliot)
Número de empleados181
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 31
Dirección117 avenue de Luminy
CiudadMARSEILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal13009
Teléfono33430303030
Sitio Webhttps://www.innate-pharma.com/
Símbolo de cotizaciónIPHA
Fecha de salida a bolsaOct 31, 2006
Director ejecutivoDickinson (Jonathan Elliot)

Ejecutivos de Innate Pharma SA

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
--
--
Ms. Odile Laurent
Ms. Odile Laurent
Vice President - Human Resources, Member of the Leadership Team
Vice President - Human Resources, Member of the Leadership Team
--
--
Ms. Pascale Boissel
Ms. Pascale Boissel
Vice Independent Chairman of the Board
Vice Independent Chairman of the Board
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Independent Director, Representative of Bpifrance Participations
Independent Director, Representative of Bpifrance Participations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Innate Pharma SA?

Los cinco principales accionistas de Innate Pharma SA son: Mr. Gilles Brisson

¿Cuántas instituciones poseen acciones de Innate Pharma SA (IPHA)?

A fecha de 2026Q1, 22 instituciones poseen acciones de Innate Pharma SA, con un valor de mercado combinado de aproximadamente 336.10K, lo que representa el 0.37% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 136136.00.
tradingkey.logo
Advertencia de Riesgo: Nuestro sitio web y aplicación móvil solo proporcionan información general sobre ciertos productos de inversión. Finsights no proporciona, y la provisión de dicha información no debe interpretarse como que Finsights proporciona, asesoramiento financiero o recomendación para cualquier producto de inversión.
Los productos de inversión están sujetos a riesgos de inversión significativos, incluida la posible pérdida del monto principal invertido y pueden no ser adecuados para todos. El rendimiento pasado de los productos de inversión no es indicativo de su rendimiento futuro.
Finsights puede permitir que anunciantes o afiliados de terceros coloquen o entreguen anuncios en nuestro sitio web o aplicación móvil o en cualquier parte de los mismos y puede ser compensado por ellos en función de su interacción con los anuncios.
© Derechos de autor: FINSIGHTS MEDIA PTE. LTD. Todos los derechos reservados.